OFE 4027

ITW

CASE NO: ON0146A NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Brian C. Carey

Type or print name

Signature

Art Unit: 1645

Examiner: S. DEVI

May 23, 2006

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ROSOK ET AL.

APPLICATION NO: 08/905,293

FILED: AUGUST 1, 1997

FOR: A METHOD FOR INHIBITING IMMUNOGLOBULIN-INDUCED

TOXICITY RESULTING FROM THE USE OF IMMUNOGLOBULINS

IN THERAPY AND IN VIVO DIAGNOSIS

Assistant Commissioner for Patents Washington, D.C. 20231

Amendment Under 37 C.F.R. §1.111 and Response to Notice to Comply

Dear Sir.

In response to the May 8, 2006 "Notice to Comply With Requirement For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Disclosures," (hereinafter "Notice to Comply"), Applicants submit herewith: 1) a substitute computer readable form ("CRF") copy of a Sequence Listing and paper copy of the same; and 2) an amendment directing entry of the substitute Sequence Listing into the specification.

The time for responding is June 8, 2006, thus this response is timely filed. No fee is believed to be due at this time. Should the Office determine that fees are due, the Commissioner is hereby authorized to charge any additional fees under to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.